Anecortave Acetate Versus Placebo in AMD Patients Following PDT
This study has been completed.
Information provided by:
First received: June 28, 2006
Last updated: August 4, 2008
Last verified: August 2008
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.
Drug: anecortave acetate
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
||Anecortave Acetate Versus Placebo in AMD Patients Following PDT
Primary Outcome Measures:
- Mean change from the baseline in logMAR visual acuity score at Month 6
Secondary Outcome Measures:
- % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2001 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||50 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346866
|Beachwood, Ohio, United States, 44122 |
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 28, 2006
||August 4, 2008
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 22, 2014
Angiogenesis Modulating Agents
Physiological Effects of Drugs